Global Ovarian Cancer Drugs Market 2019-2023
SKU ID :TNV-14770463 | Published Date: 01-Feb-2019 | No. of pages: 117Description
About this market
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view our report.
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Market Overview
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
TOC
Tables & Figures
Companies
- PRICE
-
$2500$4000Buy Now